Final patient dosed in SOLACE phase 3 trial

The last patient has been dosed in the SOLACE phase 3 clinical trial of topical ocular reproxalap in noninfectious anterior uveitis.

Time to cure without rescue therapy is the primary outcome measure of the randomized, multicenter, double-masked, parallel-group vehicle-controlled trial, according to a press release from Aldeyra Therapeutics.

“As a first-in-class novel compound with a unique product profile, reproxalap has the potential to treat patients without the toxicities commonly associated with corticosteroids,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release.

Results from the trial are expected to be announced later this year.

The last patient has been dosed in the SOLACE phase 3 clinical trial of topical ocular reproxalap in noninfectious anterior uveitis.

Time to cure without rescue therapy is the primary outcome measure of the randomized, multicenter, double-masked, parallel-group vehicle-controlled trial, according to a press release from Aldeyra Therapeutics.

“As a first-in-class novel compound with a unique product profile, reproxalap has the potential to treat patients without the toxicities commonly associated with corticosteroids,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release.

Results from the trial are expected to be announced later this year.